{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:41:11Z","timestamp":1784202071282,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773968"],"award-info":[{"award-number":["81773968"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.wneu.2021.09.094","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T10:13:40Z","timestamp":1632737620000},"page":"e66-e76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Integrated Analysis of Transcriptome and Differential Methylation of Neurofibromatosis Type 2 Vestibular Schwannomas"],"prefix":"10.1016","volume":"157","author":[{"given":"Jianwei","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yansong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl_5","key":"10.1016\/j.wneu.2021.09.094_bib1","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014","volume":"19","author":"Ostrom","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2021.09.094_bib2","first-page":"98","article-title":"Neurofibromatosis: a review of NF1, NF2, and schwannomatosis","volume":"5","author":"Kresak","year":"2016","journal-title":"J\u00a0Pediatr Genet"},{"key":"10.1016\/j.wneu.2021.09.094_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/neuonc\/noz153","article-title":"EANO guideline on the diagnosis and treatment of vestibular schwannoma","volume":"22","author":"Goldbrunner","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2021.09.094_bib4","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3390\/ijms22020690","article-title":"Neurofibromatosis type 2 (NF2) and the implications for vestibular schwannoma and meningioma pathogenesis","volume":"22","author":"Bachir","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.wneu.2021.09.094_bib5","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00018-017-2493-1","article-title":"Epigenetics: a link between addiction and social environment","volume":"74","author":"Ajonijebu","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.wneu.2021.09.094_bib6","first-page":"856157","article-title":"The molecular biology of vestibular schwannomas and its association with hearing loss: a review","volume":"2012","author":"Celis-Aguilar","year":"2012","journal-title":"Genet Res Int"},{"key":"10.1016\/j.wneu.2021.09.094_bib7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrg3230","article-title":"Functions of DNA methylation: islands, start sites, gene bodies and beyond","volume":"13","author":"Jones","year":"2012","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.wneu.2021.09.094_bib8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2443.2001.00432.x","article-title":"Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma","volume":"6","author":"Kino","year":"2001","journal-title":"Genes Cells"},{"key":"10.1016\/j.wneu.2021.09.094_bib9","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00401-016-1540-6","article-title":"Methylation-based classification of benign and malignant peripheral nerve sheath tumors","volume":"131","author":"R\u00f6hrich","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.wneu.2021.09.094_bib10","first-page":"5601","article-title":"CpG island methylation in sporadic and neurofibromatis type 2-associated schwannomas","volume":"9","author":"Gonzalez-Gomez","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2021.09.094_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/DDDT.S280069","article-title":"A\u00a0review of drug therapy in vestibular schwannoma","volume":"15","author":"Long","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.wneu.2021.09.094_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/neuonc\/noz153","article-title":"EANO guideline on the diagnosis and treatment of vestibular schwannoma","volume":"22","author":"Goldbrunner","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2021.09.094_bib13","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/hmg\/3.6.885","article-title":"Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas","volume":"3","author":"Sainz","year":"1994","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.wneu.2021.09.094_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00401-012-1056-7","article-title":"Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition","volume":"125","author":"Prada","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.wneu.2021.09.094_bib15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11060-019-03388-5","article-title":"Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas","volume":"146","author":"Tamura","year":"2020","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2021.09.094_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.wneu.2021.09.094_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13046-015-0249-z","article-title":"Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II-IV gliomas","volume":"34","author":"Wang","year":"2015","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.wneu.2021.09.094_bib18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1126\/science.1083558","article-title":"Induction of tumors in mice by genomic hypomethylation","volume":"300","author":"Gaudet","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.wneu.2021.09.094_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ijc.29684","article-title":"Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes","volume":"38","author":"Gy\u0151rffy","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.wneu.2021.09.094_bib20","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.1074\/jbc.273.13.7757","article-title":"Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli","volume":"273","author":"Shaw","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.wneu.2021.09.094_bib21","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1073\/pnas.0700044104","article-title":"The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion","volume":"104","author":"McLaughlin","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.wneu.2021.09.094_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12964-020-00544-7","article-title":"Merlin regulates signaling events at the nexus of development and cancer","volume":"18","author":"Mota","year":"2020","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.wneu.2021.09.094_bib23","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1158\/0008-5472.CAN-16-2834","article-title":"An essential role for the tumor-suppressor merlin in regulating fatty acid synthesis","volume":"77","author":"Stepanova","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.wneu.2021.09.094_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jsbmb.2004.10.013","article-title":"Androgens, lipogenesis and prostate cancer","volume":"92","author":"Swinnen","year":"2004","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.wneu.2021.09.094_bib25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ccr.2011.02.017","article-title":"A\u00a0tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions","volume":"19","author":"Yi","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.wneu.2021.09.094_bib26","doi-asserted-by":"crossref","first-page":"18200","DOI":"10.1073\/pnas.0405971102","article-title":"Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L","volume":"101","author":"Rong","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.wneu.2021.09.094_bib27","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.bbrc.2005.12.122","article-title":"Merlin inhibits growth hormone-regulated Raf\u2013ERKs pathways by binding to Grb2 protein","volume":"340","author":"Lim","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.wneu.2021.09.094_bib28","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/00129492-200209000-00022","article-title":"cDNA microarray analysis of vestibular schwannomas","volume":"23","author":"Welling","year":"2002","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.wneu.2021.09.094_bib29","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/00005537-200209000-00004","article-title":"Retinoblastoma - cyclin-dependent kinase pathway deregulation in vestibular schwannomas","volume":"112","author":"Lasak","year":"2002","journal-title":"Laryngoscope"},{"key":"10.1016\/j.wneu.2021.09.094_bib30","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1038\/onc.2015.404","article-title":"The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.wneu.2021.09.094_bib31","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1242\/jcs.114.9.1609","article-title":"KSR: a MAPK scaffold of the Ras pathway?","volume":"114","author":"Morrison","year":"2001","journal-title":"J\u00a0Cell Sci"},{"key":"10.1016\/j.wneu.2021.09.094_bib32","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.cell.2009.07.049","article-title":"Schwann cell precursors from nerve innervation are a cellular origin of melanocytes in skin","volume":"139","author":"Adameyko","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.wneu.2021.09.094_bib33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00000478-198112000-00001","article-title":"Cellular schwannoma: a variety of schwannoma sometimes mistaken for a malignant tumor","volume":"5","author":"Woodruff","year":"1981","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.wneu.2021.09.094_bib34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00000478-199003000-00002","article-title":"Psammomatous melanotic schwannoma. A distinctive, heritable tumor with special associations, including cardiac myxoma and the Cushing syndrome","volume":"14","author":"Carney","year":"1990","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.wneu.2021.09.094_bib35","first-page":"153","article-title":"Melanotic schwannoma of the acoustic nerve","volume":"110","author":"Miller","year":"1986","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.wneu.2021.09.094_bib36","author":"Fan"},{"key":"10.1016\/j.wneu.2021.09.094_bib37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.drup.2007.11.003","article-title":"Targeting the PI3K\/Akt\/mTOR pathway: effective combinations and clinical considerations","volume":"11","author":"Lopiccolo","year":"2008","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.wneu.2021.09.094_bib38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/mao.0b013e31815d4429","article-title":"ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy","volume":"29","author":"Doherty","year":"2008","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.wneu.2021.09.094_bib39","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","article-title":"Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients","volume":"31","author":"Plotkin","year":"2010","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.wneu.2021.09.094_bib40","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.wneu.2021.09.094_bib41","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.wneu.2021.09.094_bib42","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2353\/ajpath.2010.090356","article-title":"Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth","volume":"176","author":"Amann","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.wneu.2021.09.094_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0378-1119(94)00562-7","article-title":"The involvement of the chromosome 11q13 region in human malignancies: cyclin D1, and EMS1, are two new candidate oncogenes-a review","volume":"159","author":"Schuuring","year":"1995","journal-title":"Gene"},{"key":"10.1016\/j.wneu.2021.09.094_bib44","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/jcp.21791","article-title":"Nuclear cyclin D1: an oncogenic driver in human cancer","volume":"220","author":"Kim","year":"2009","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.wneu.2021.09.094_bib45","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13046-020-01714-8","article-title":"RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer","volume":"39","author":"Yang","year":"2020","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.wneu.2021.09.094_bib46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mc.23292","article-title":"HPV-16\/18 E6-induced APOBEC3B expression associates with proliferation of cervical cancer cells and hypomethylation of Cyclin D1","volume":"60","author":"Fan","year":"2021","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.wneu.2021.09.094_bib47","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/MAO.0b013e31814b2285","article-title":"Cyclin D1 expression and histopathologic features in vestibular schwannomas","volume":"28","author":"Lassaletta","year":"2007","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.wneu.2021.09.094_bib48","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1080\/10428190802007734","article-title":"Expression profiling reveals specific gene expression signatures in gastric MALT lymphomas","volume":"49","author":"Huynh","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.wneu.2021.09.094_bib49","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10549-020-05874-1","article-title":"Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer","volume":"184","author":"Kim","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.wneu.2021.09.094_bib50","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/nan.12127","article-title":"The protein expression profile of meningioma cells is associated with distinct cytogenetic tumour subgroups","volume":"41","author":"Domingues","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.wneu.2021.09.094_bib51","doi-asserted-by":"crossref","first-page":"378-393","DOI":"10.1016\/j.tins.2016.03.005","article-title":"Emerging roles for csf-1 receptor and its ligands in the nervous system","volume":"39","author":"Chitu","year":"2016","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.wneu.2021.09.094_bib52","doi-asserted-by":"crossref","first-page":"e25218","DOI":"10.1097\/MD.0000000000025218","article-title":"Overexpression of macrophage-colony stimulating factor-1 receptor as a prognostic factor for survival in cancer: a systematic review and meta-analysis","volume":"100","author":"Mo","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.wneu.2021.09.094_bib53","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","article-title":"Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas","volume":"122","author":"Goutagny","year":"2015","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2021.09.094_bib54","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1007\/s10637-021-01093-7","article-title":"Vorolanib (X-82), an oral anti-VEGFR\/PDGFR\/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study","volume":"39","author":"Pedersen","year":"2021","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.wneu.2021.09.094_bib55","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1038\/onc.2011.38","article-title":"From Rous sarcoma virus to plasminogen activator, src oncogene and cancer management","volume":"30","author":"Sudol","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.wneu.2021.09.094_bib56","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1164\/rccm.200703-390OC","article-title":"Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer","volume":"177","author":"Wang","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.wneu.2021.09.094_bib57","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1200\/JCO.2005.05.1912","article-title":"Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer","volume":"24","author":"Urban","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2021.09.094_bib58","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/MAO.0b013e31817f7398","article-title":"The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study","volume":"29","author":"Clark","year":"2008","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.wneu.2021.09.094_bib59","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/ijc.32859","article-title":"Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer","volume":"147","author":"Sonnenblick","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.wneu.2021.09.094_bib60","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N\u00a0Engl J Med"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875021014376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875021014376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:04:45Z","timestamp":1761815085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875021014376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":60,"alternative-id":["S1878875021014376"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2021.09.094","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated Analysis of Transcriptome and Differential Methylation of Neurofibromatosis Type 2 Vestibular Schwannomas","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2021.09.094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}